{"success":true,"data":{"pressRelease":{"id":"19051","rtpr_id":"nGNX7mkShf","ticker":"SLNO","exchange":"NASDAQ","all_tickers":["SLNO"],"title":"SLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff Deadline","author":"Globe Newswire","published_at":"2026-05-04T12:45:38.098Z","article_body":"SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- National shareholder rights\nlaw firm Hagens Berman reminds investors in Soleno Therapeutics, Inc.\n(NASDAQ: SLNO) of the pending securities class action and the upcoming May 5,\n2026 lead plaintiff deadline. The firm urges investors who purchased Soleno\ncommon stock between March 26, 2025, and November 4, 2025 (the “Class\nPeriod”), and suffered significant losses to submit your losses now\n(https://www.globenewswire.com/Tracker?data=4XWp3fL7nfG6HD_lBnGPQcNRNyk84HwnxLys_lFQftKAdDRSDIHfqL018tSi5DzKYIvmQLAIrcI5jttRUj6sZz-HnN2XDvlcNOoYN7emyDZjG0EbEmpKhb8FdILsSe-9).\n\nCase Name: City of Pontiac Police & Fire Ret. Sys. v. Soleno Therapeutics,\nInc., et al.\nCase No.: 26-cv-01979 (N.D. Cal.)\nContact: Reed Kathrein\n(https://www.globenewswire.com/Tracker?data=1OaQB0GAkLt0feLZg_7ksopHDxTs63PypKiTz4wfHvz_RZ0FiL4srZHuSVDF64bKJvae93w1cD46nr0BV_ZG8bW0R_ej-Na566qMT0Ytoja-Ugb7VinrtafevVF4wddH)\n| 844-916-0895 | Submit SLNO Losses Here\n(https://www.globenewswire.com/Tracker?data=qcnnkJG9kfyw32iY_LMAiAgwaKVkGbrTsb0PktHQeWUgJhH-Te1SHyllUqEbtpnrW9NteXdurWPMZKQ5Ibn7Ng-zCuMihPPHtbl4Fb4bWLFqKI3ljLx3tA0yle1pIs5V)\n\nThe Allegations: Concealed Safety Risks and “Hocus-Pocus” Metrics:\n\nThe Soleno class action focuses on the company’s repeated assurances\nregarding the safety, efficacy, and commercial launch of its flagship product,\nVYKAT™ XR (DCCR), for the treatment of Prader-Willi syndrome (PWS).\n\nThe complaint alleges that throughout the Class Period, Soleno misrepresented\nthe commercial viability of DCCR by failing to disclose:\n* Systemic Safety Omissions: The company allegedly downplayed significant\nevidence of safety concerns, including excess fluid retention and potential\nheart failure in children using the drug.\n\n* Integrity Red Flags: A report by activist short seller Scorpion Capital\nhighlighted that Soleno’s Phase 3 clinical trials were purportedly reliant\non a controversial physician in Gainesville, Florida, whose data exhibited\nirregularities consistent with data integrity failures.\n\n* Inflated Launch Metrics: While Soleno claimed the DCCR launch \"definitely\nexceeded our expectations,\" the complaint alleges that the \"start forms\" were\nartificially fueled by an \"invisible hand\" rather than genuine market demand.\nThe Alleged Corrective Disclosures and Stock Declines\n\nOn August 15, 2025, activist short seller Scorpion Capital published a report\ntitled “Russian Roulette With Prader-Willi Children,” detailing widespread\nadverse patient reactions and investigator skepticism. This report triggered\nan immediate double-digit decline in the stock price.\n\nThe truth allegedly fully materialized on November 4, 2025, when Soleno\nreported Q3 2025 financial results. Management admitted to a disruption in\nDCCR’s launch trajectory, specifically acknowledging a lower number of\npatient start forms and increased discontinuations. On this news, SLNO stock\nplummeted 27% in a single day.\n\n“Our investigation centers on the complaint’s claims that Soleno allegedly\nbypassed critical safety protocols and used questionable metrics to maintain\nan inflated stock price,” said Reed Kathrein\n(https://www.globenewswire.com/Tracker?data=1OaQB0GAkLt0feLZg_7ksiyCqQZnBQnpj42vwroncoSn44fJ3w9b4uCUXgjgh5yNpNg3zda2sLJbZ13iH7QO5rFhhIPZZYp5chprRmQhyaYAETv0885yMu3902SVEFlE),\nthe Hagens Berman partner leading the firm’s investigation of the alleged\nclaims.\n\nCritical Deadline: May 5, 2026\n\nIf you purchased Soleno stock during the Class Period and suffered a\nsignificant loss, you have until May 5, 2026, to petition the Court to serve\nas lead plaintiff.\n\nIf you invested in Soleno and have substantial losses, or have knowledge that\nmay assist the firm’s investigation, submit your losses now\n(https://www.globenewswire.com/Tracker?data=4XWp3fL7nfG6HD_lBnGPQcNRNyk84HwnxLys_lFQftIi8JRusZxd1vg-nCHznIV2yL0bbj99dcQSODiNWGyXi__yt7p6zLazU1_4S9DXAheA1I2LzTGrz6ox9DA4xOdy)\n»\n\nIf you’d like more information and answers to frequently asked questions\nabout the Soleno case and the firm’s investigation, read more\n(https://www.globenewswire.com/Tracker?data=4C0TmlPsH6Ds-CAU_zzANagG3OaWQjpf3VKQVRx4NTIvLHYucY-b1w-EQMDYw7bvGYBABpXWI2gEqnvyW4uJlx02Hz1QGmnv2tV9Q1N6ht5E37B_P8f3J67EEwtJe_TC_LJsfFrZINZdaADGWO2RzmLFghnH2hH9dlFCsG6J83w=)\n»\n\nWhistleblowers: Persons with non-public information regarding Soleno should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email SLNO@hbsslaw.com.\n\nAbout Hagens Berman\n(https://www.globenewswire.com/Tracker?data=TMlfL4gZRj4IJRASrozArq_bZ2d2SzglX782D2ctXadmTAzx9Gww3eGhxHgOkMRDrkfYU7IEYGVt6XpuNS42yQak5DU1Z94hdvAj03NCenI=)\nHagens Berman is a global plaintiffs’ rights complex litigation firm\nfocusing on corporate accountability. The firm is home to a robust practice\nand represents investors as well as whistleblowers, workers, consumers and\nothers in cases achieving real results for those harmed by corporate\nnegligence and other wrongdoings. Hagens Berman’s team has secured more than\n$2.9 billion in this area of law. More about the firm and its successes can be\nfound at hbsslaw.com\n(https://www.globenewswire.com/Tracker?data=FvzR0B5ISB-YUJ0B-9F91iD6b1XBD0IghNZK3Agt3QE-DYQXyupisQjLPTodPuYWAKDiQW8RX9PIIuSaJb9DVQ==).\nFollow the firm for updates and news at @ClassActionLaw. \n\nContact: \nReed Kathrein, 844-916-0895\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2c81cd72-0ffb-43c9-9d0f-b622c3e44e43)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7mkShf","title":"SLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff Deadline","author":"Globe Newswire","ticker":"SLNO","created":"2026-05-04T12:45:38.098Z","tickers":["SLNO"],"exchange":"NASDAQ","article_body":"SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- National shareholder rights\nlaw firm Hagens Berman reminds investors in Soleno Therapeutics, Inc.\n(NASDAQ: SLNO) of the pending securities class action and the upcoming May 5,\n2026 lead plaintiff deadline. The firm urges investors who purchased Soleno\ncommon stock between March 26, 2025, and November 4, 2025 (the “Class\nPeriod”), and suffered significant losses to submit your losses now\n(https://www.globenewswire.com/Tracker?data=4XWp3fL7nfG6HD_lBnGPQcNRNyk84HwnxLys_lFQftKAdDRSDIHfqL018tSi5DzKYIvmQLAIrcI5jttRUj6sZz-HnN2XDvlcNOoYN7emyDZjG0EbEmpKhb8FdILsSe-9).\n\nCase Name: City of Pontiac Police & Fire Ret. Sys. v. Soleno Therapeutics,\nInc., et al.\nCase No.: 26-cv-01979 (N.D. Cal.)\nContact: Reed Kathrein\n(https://www.globenewswire.com/Tracker?data=1OaQB0GAkLt0feLZg_7ksopHDxTs63PypKiTz4wfHvz_RZ0FiL4srZHuSVDF64bKJvae93w1cD46nr0BV_ZG8bW0R_ej-Na566qMT0Ytoja-Ugb7VinrtafevVF4wddH)\n| 844-916-0895 | Submit SLNO Losses Here\n(https://www.globenewswire.com/Tracker?data=qcnnkJG9kfyw32iY_LMAiAgwaKVkGbrTsb0PktHQeWUgJhH-Te1SHyllUqEbtpnrW9NteXdurWPMZKQ5Ibn7Ng-zCuMihPPHtbl4Fb4bWLFqKI3ljLx3tA0yle1pIs5V)\n\nThe Allegations: Concealed Safety Risks and “Hocus-Pocus” Metrics:\n\nThe Soleno class action focuses on the company’s repeated assurances\nregarding the safety, efficacy, and commercial launch of its flagship product,\nVYKAT™ XR (DCCR), for the treatment of Prader-Willi syndrome (PWS).\n\nThe complaint alleges that throughout the Class Period, Soleno misrepresented\nthe commercial viability of DCCR by failing to disclose:\n* Systemic Safety Omissions: The company allegedly downplayed significant\nevidence of safety concerns, including excess fluid retention and potential\nheart failure in children using the drug.\n\n* Integrity Red Flags: A report by activist short seller Scorpion Capital\nhighlighted that Soleno’s Phase 3 clinical trials were purportedly reliant\non a controversial physician in Gainesville, Florida, whose data exhibited\nirregularities consistent with data integrity failures.\n\n* Inflated Launch Metrics: While Soleno claimed the DCCR launch \"definitely\nexceeded our expectations,\" the complaint alleges that the \"start forms\" were\nartificially fueled by an \"invisible hand\" rather than genuine market demand.\nThe Alleged Corrective Disclosures and Stock Declines\n\nOn August 15, 2025, activist short seller Scorpion Capital published a report\ntitled “Russian Roulette With Prader-Willi Children,” detailing widespread\nadverse patient reactions and investigator skepticism. This report triggered\nan immediate double-digit decline in the stock price.\n\nThe truth allegedly fully materialized on November 4, 2025, when Soleno\nreported Q3 2025 financial results. Management admitted to a disruption in\nDCCR’s launch trajectory, specifically acknowledging a lower number of\npatient start forms and increased discontinuations. On this news, SLNO stock\nplummeted 27% in a single day.\n\n“Our investigation centers on the complaint’s claims that Soleno allegedly\nbypassed critical safety protocols and used questionable metrics to maintain\nan inflated stock price,” said Reed Kathrein\n(https://www.globenewswire.com/Tracker?data=1OaQB0GAkLt0feLZg_7ksiyCqQZnBQnpj42vwroncoSn44fJ3w9b4uCUXgjgh5yNpNg3zda2sLJbZ13iH7QO5rFhhIPZZYp5chprRmQhyaYAETv0885yMu3902SVEFlE),\nthe Hagens Berman partner leading the firm’s investigation of the alleged\nclaims.\n\nCritical Deadline: May 5, 2026\n\nIf you purchased Soleno stock during the Class Period and suffered a\nsignificant loss, you have until May 5, 2026, to petition the Court to serve\nas lead plaintiff.\n\nIf you invested in Soleno and have substantial losses, or have knowledge that\nmay assist the firm’s investigation, submit your losses now\n(https://www.globenewswire.com/Tracker?data=4XWp3fL7nfG6HD_lBnGPQcNRNyk84HwnxLys_lFQftIi8JRusZxd1vg-nCHznIV2yL0bbj99dcQSODiNWGyXi__yt7p6zLazU1_4S9DXAheA1I2LzTGrz6ox9DA4xOdy)\n»\n\nIf you’d like more information and answers to frequently asked questions\nabout the Soleno case and the firm’s investigation, read more\n(https://www.globenewswire.com/Tracker?data=4C0TmlPsH6Ds-CAU_zzANagG3OaWQjpf3VKQVRx4NTIvLHYucY-b1w-EQMDYw7bvGYBABpXWI2gEqnvyW4uJlx02Hz1QGmnv2tV9Q1N6ht5E37B_P8f3J67EEwtJe_TC_LJsfFrZINZdaADGWO2RzmLFghnH2hH9dlFCsG6J83w=)\n»\n\nWhistleblowers: Persons with non-public information regarding Soleno should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email SLNO@hbsslaw.com.\n\nAbout Hagens Berman\n(https://www.globenewswire.com/Tracker?data=TMlfL4gZRj4IJRASrozArq_bZ2d2SzglX782D2ctXadmTAzx9Gww3eGhxHgOkMRDrkfYU7IEYGVt6XpuNS42yQak5DU1Z94hdvAj03NCenI=)\nHagens Berman is a global plaintiffs’ rights complex litigation firm\nfocusing on corporate accountability. The firm is home to a robust practice\nand represents investors as well as whistleblowers, workers, consumers and\nothers in cases achieving real results for those harmed by corporate\nnegligence and other wrongdoings. Hagens Berman’s team has secured more than\n$2.9 billion in this area of law. More about the firm and its successes can be\nfound at hbsslaw.com\n(https://www.globenewswire.com/Tracker?data=FvzR0B5ISB-YUJ0B-9F91iD6b1XBD0IghNZK3Agt3QE-DYQXyupisQjLPTodPuYWAKDiQW8RX9PIIuSaJb9DVQ==).\nFollow the firm for updates and news at @ClassActionLaw. \n\nContact: \nReed Kathrein, 844-916-0895\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/2c81cd72-0ffb-43c9-9d0f-b622c3e44e43)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-04T12:45:38.138046842Z","server_sent_at_ms":1777898738138},"received_at":"2026-05-04T12:45:38.197Z","source_url":null},"analysis":{"id":"13849","press_release_id":"19051","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Hagens Berman issued a solicitation notice reminding Soleno Therapeutics investors of a pending securities class action and a May 5, 2026 lead plaintiff deadline.\n\nThe complaint alleges the company misrepresented the safety and commercial viability of its drug VYKAT™ XR, failing to disclose safety risks and relying on questionable metrics.\n\nThis is a law-firm solicitation for shareholders with losses; it is not a disclosure from the issuer.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Reed Kathrein","role":"Partner at Hagens Berman"}],"products":["VYKAT™ XR","DCCR"],"companies":[{"name":"Soleno Therapeutics, Inc.","ticker":"SLNO","relationship":"defendant"},{"name":"Hagens Berman","relationship":"plaintiff law firm"},{"name":"Scorpion Capital","relationship":"activist short seller"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Hagens Berman. No new disclosure from the issuer; no certified class or settlement announced. Standard lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"SLNO"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Hagens Berman issued a solicitation notice reminding Soleno Therapeutics investors of a pending securities class action and a May 5, 2026 lead plaintiff deadline.\n\nThe complaint alleges the company misrepresented the safety and commercial viability of its drug VYKAT™ XR, failing to disclose safety risks and relying on questionable metrics.\n\nThis is a law-firm solicitation for shareholders with losses; it is not a disclosure from the issuer.","key_figures":{},"named_entities":{"people":[{"name":"Reed Kathrein","role":"Partner at Hagens Berman"}],"products":["VYKAT™ XR","DCCR"],"companies":[{"name":"Soleno Therapeutics, Inc.","ticker":"SLNO","relationship":"defendant"},{"name":"Hagens Berman","relationship":"plaintiff law firm"},{"name":"Scorpion Capital","relationship":"activist short seller"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T16:19:04.759Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":145568,"modelName":"glm-4.7"}}